Bicara Therapeutics Inc. (BCAX)

Over the past six months, Bicara Therapeutics' stock has been influenced by positive clinical data, regulatory designations, analyst coverage, financial reporting, presentations, and stock performance. Positive Phase 1b data and FDA Breakthrough Therapy Designation for ficerafusp alfa boosted the stock. Analyst ratings were mixed, with some initiating coverage with "Buy" recommendations while others expressed concerns. The company reported quarterly earnings that missed estimates. BCAX shares have increased by 1.1% since the start of 2025, with a 60.64% increase over the past six months.

As a clinical-stage biopharmaceutical company, Bicara Therapeutics, Inc. does not have products or services currently on the market that would be subject to typical demand seasonality. Its revenue generation is primarily tied to research and development milestones, partnerships, and potential future drug approvals.

Bicara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, operating in the Health Technology sector, specifically in the Biotechnology and Pharmaceutical industries. Their primary product, ficerafusp alfa (BCA101), is a first-in-class EGFR/TGF-β-trap bifunctional antibody in clinical development for various tumor types, with an initial focus on head and neck squamous cell carcinoma (HNSCC).

Bicara Therapeutics, Inc., founded in 2018, is headquartered in Boston, Massachusetts, United States, and serves patients worldwide.

Bicara Therapeutics' brand reputation has been positively influenced by the FDA Breakthrough Therapy Designation for ficerafusp alfa, positive preliminary Phase 1b data, advancement to Phase 3 with optimal dose selection, and inclusion in major biotechnology indices. While some analysts have expressed concerns about the competitive landscape, the overall news sentiment for Bicara Therapeutics has been positive.

Bicara Therapeutics Inc. is predominantly owned by institutional shareholders, who hold 91.63% of the stock. Insiders own 38.61%, while retail investors hold 0.00%. Major institutional owners include RA Capital Management, L.P., Siren, L.L.C., Vestal Point Capital, LP, Biocon Ltd, Red Tree Management, LLC, TPG GP A, LLC, FMR LLC, Deep Track Capital, LP, BlackRock, Inc., Omega Fund Management, LLC, and Vanguard Group Inc. The largest individual shareholder is Kiran Mazumdarshaw, who owns 6.30 million shares, representing 11.50% of the company.